Impact of Amlitelimab (An Anti-OX40 Ligand Antibody) on Maintenance of Itch Response in Atopic Dermatitis: Results From the 52-Week STREAM-AD Phase 2b Study. J of Skin [Internet]. 2025 Nov. 10 [cited 2026 Jan. 14];9(6):s604. Available from: https://skin.dermsquared.com/skin/article/view/3883